- Home
- ADAM vs AVTX Comparison
ADAM vs AVTX Comparison
Compare ADAM & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAM | AVTX |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.0M | 710.1M |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADAM | AVTX |
|---|---|---|
| Price | $6.01 | $7.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $11.50 | ★ $36.60 |
| AVG Volume (30 Days) | 1.0M | ★ 2.7M |
| Earning Date | 10-28-2026 | 11-13-2026 |
| Dividend Yield | ★ 18.35% | N/A |
| EPS Growth | ★ 196.49 | 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $7.53 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $6.55 | $6.53 |
| 52 Week High | $10.36 | $24.27 |
Technical Indicators
Market Signals| Indicator | ADAM | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.31 | 24.33 |
| Support Level | N/A | $6.53 |
| Resistance Level | $9.36 | $20.54 |
| Average True Range (ATR) | 0.31 | 0.83 |
| MACD | -0.09 | -0.18 |
| Stochastic Oscillator | 5.00 | 12.33 |
Price Performance
Historical ComparisonAbout ADAM Adamas Trust Inc.
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.